Changes in haemostatic parameters during the menstrual cycle and drospirenone-containing oral contraceptive use.
Not Applicable
- Conditions
- procoagulant changes during drospirenone-containing oral contraceptive
- Registration Number
- DRKS00005291
- Lead Sponsor
- niversitätsklinikum Magdeburg Universitätsfrauenklinik
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 14
Inclusion Criteria
No hormonal contraceptives for at least two month prior to start the study.
Exclusion Criteria
Pregnancy, lactation, a personal or family history of VT, coagulation disorders or use of medication that might interfere with blood coagulation, contraindications to hormonal contraception.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endogenous thrombin potential, APC resistance, the function of the tissue factor pathway inhibitor-system <br><br>
- Secondary Outcome Measures
Name Time Method Plasma levels of prothrombin, antithrombin, factor V, factor X, factor VIII, protein C, protein S(total and free) and tissue factor pathway inhibitor (full-length and free).<br>